95 related articles for article (PubMed ID: 3502169)
1. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
[TBL] [Abstract][Full Text] [Related]
2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
3. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
4. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
Lotzová E; Savary CA; Herberman RB
J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
6. Immunologic and clinical aspects of natural killer cells in human leukemia.
Lotzová E; Savary CA; Pollock RE; Fuchshuber P
Nat Immun Cell Growth Regul; 1990; 9(3):173-81. PubMed ID: 2370877
[TBL] [Abstract][Full Text] [Related]
7. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
8. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
[TBL] [Abstract][Full Text] [Related]
9. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3.
Jung G; Martin DE; Müller-Eberhard HJ
J Immunol; 1987 Jul; 139(2):639-44. PubMed ID: 3110277
[TBL] [Abstract][Full Text] [Related]
10. Induction of monocyte procoagulant activity with OKT3 antibody.
Iitaka M; Iwatani Y; Row VV; Volpé R
J Immunol; 1987 Sep; 139(5):1617-23. PubMed ID: 3114371
[TBL] [Abstract][Full Text] [Related]
11. Generation of NK cell activity from human bone marrow.
Lotzová E; Savary CA
J Immunol; 1987 Jul; 139(1):279-84. PubMed ID: 3495600
[TBL] [Abstract][Full Text] [Related]
12. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
13. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
Hogan PG; Hapel AJ; Doe WF
J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and clinical application of activated NK cells.
Lotzová E
Med Oncol Tumor Pharmacother; 1989; 6(1):93-8. PubMed ID: 2786121
[TBL] [Abstract][Full Text] [Related]
16. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
17. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
Ozdemir O; Savaşan S
Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
[TBL] [Abstract][Full Text] [Related]
18. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
[TBL] [Abstract][Full Text] [Related]
20. Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2.
Peest D; Leo R; Deicher H
Stem Cells; 1995 Aug; 13 Suppl 2():72-6. PubMed ID: 8520515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
